Literature DB >> 16138960

Therapy for pediatric myocarditis.

Charles E Canter1.   

Abstract

Pediatric myocarditis is most often associated with the acute or subacute onset of congestive heart failure in a previously healthy child. Myocarditis presenting with acute, severe symptomatology, termed fulminant myocarditis, has a high rate of recovery. Aggressive supportive care is indicated in fulminant myocarditis, including mechanical circulatory support. For subacute heart failure, supportive care remains the mainstay of therapy for myocarditis. A number of uncontrolled pediatric studies using both immunosuppressive therapy and/or immunomodulating therapy with intravenous gamma globulin have suggested these therapies are safe and useful in treating pediatric myocarditis. However, translating these results into recommended, routine therapy for pediatric myocarditis is complicated by the high rate of spontaneous improvement of myocarditis with supportive care, and the lack of demonstrable benefit for immunosuppressive and immunomodulating therapies in blinded, randomized, placebo-controlled trials in adult myocarditis. Heart transplantation remains the final therapeutic option for children with myocarditis and intractable severe heart failure.

Entities:  

Year:  2005        PMID: 16138960     DOI: 10.1007/s11936-005-0025-z

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  57 in total

1.  Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results.

Authors:  R Wojnicz; E Nowalany-Kozielska; C Wojciechowska; G Glanowska; P Wilczewski; T Niklewski; M Zembala; L Polonski; M M Rozek; J Wodniecki
Journal:  Circulation       Date:  2001-07-03       Impact factor: 29.690

2.  Experience and result of extracorporeal membrane oxygenation in treating fulminant myocarditis with shock: what mechanical support should be considered first?

Authors:  Yih-Sharng Chen; Hsi-Yu Yu; Shu-Chien Huang; Kaung-Ming Chiu; Tzu-Yu Lin; Lin-Ping Lai; Fang-Yue Lin; Shoei-Shan Wang; Shu-Hsun Chu; Wen-Je Ko
Journal:  J Heart Lung Transplant       Date:  2005-01       Impact factor: 10.247

3.  High doses of digitalis increase the myocardial production of proinflammatory cytokines and worsen myocardial injury in viral myocarditis: a possible mechanism of digitalis toxicity.

Authors:  A Matsumori; H Igata; K Ono; A Iwasaki; T Miyamoto; R Nishio; S Sasayama
Journal:  Jpn Circ J       Date:  1999-12

Review 4.  Eosinophilic myocarditis manifesting as myocardial infarction: early diagnosis and successful treatment.

Authors:  L Galiuto; M Enriquez-Sarano; G S Reeder; H D Tazelaar; J T Li; F A Miller; G J Gleich
Journal:  Mayo Clin Proc       Date:  1997-07       Impact factor: 7.616

5.  Chronic variant of myocarditis associated with hepatitis C virus infection.

Authors:  M Okabe; K Fukuda; K Arakawa; M Kikuchi
Journal:  Circulation       Date:  1997-07-01       Impact factor: 29.690

6.  Intravenous arginine-vasopressin in children with vasodilatory shock after cardiac surgery.

Authors:  E B Rosenzweig; T J Starc; J M Chen; S Cullinane; D M Timchak; W M Gersony; D W Landry; M E Galantowicz
Journal:  Circulation       Date:  1999-11-09       Impact factor: 29.690

7.  Nesiritide use in pediatric patients with congestive heart failure.

Authors:  Brian Feingold; Yuk M Law
Journal:  J Heart Lung Transplant       Date:  2004-12       Impact factor: 10.247

8.  A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators.

Authors:  J W Mason; J B O'Connell; A Herskowitz; N R Rose; B M McManus; M E Billingham; T E Moon
Journal:  N Engl J Med       Date:  1995-08-03       Impact factor: 91.245

9.  Role of right ventricular endomyocardial biopsy in infants and children with suspected or possible myocarditis.

Authors:  S A Webber; G J Boyle; R Jaffe; R M Pickering; L B Beerman; F J Fricker
Journal:  Br Heart J       Date:  1994-10

10.  Long term follow up of children with myocarditis treated by immunosuppression and of children with dilated cardiomyopathy.

Authors:  M Giulia Gagliardi; M Bevilacqua; C Bassano; B Leonardi; R Boldrini; F Diomedi Camassei; A Fierabracci; A G Ugazio; G F Bottazzo
Journal:  Heart       Date:  2004-10       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.